Medicines shouldn’t be a luxury Take action!

Infographics: Hepatitis C

Hepatitis C Sofosbuvir

Hepatitis C Sofosbuvir Gold

Thumbnail

Press release |

25 July 2019

Cambodia

Cambodia: Simpler and more affordable treatment for hepatitis C saves lives

4 min

Thumbnail

Feature story |

25 July 2019

Ukraine

Generic medicines prove to be an affordable option in combating Ukraine’s hepatitis C epidemic

4 min

Thumbnail

Feature story

Hepatitis C HIV/AIDS Research and development Tuberculosis Vaccines

Then & Now in Access to Medicines: Changes & Challenges

4 min

In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich. Activists held a protest in front of the European Patent Office for affordable medicines at the start of proceedings on 13 September.

Press release

Press release |

05 December 2018

Europe

Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug

3 min